Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis

医学 荟萃分析 单克隆抗体 单克隆 免疫学 1型糖尿病 抗体 糖尿病 内科学 内分泌学
作者
A B Kamrul-Hasan,Sunetra Mondal,Lakshmi Nagendra,Ashmita Yadav,Fatema Tuz Zahura Aalpona,Deep Dutta
出处
期刊:Endocrine Practice [Elsevier BV]
卷期号:30 (5): 431-440 被引量:12
标识
DOI:10.1016/j.eprac.2024.03.006
摘要

ObjectiveTeplizumab has emerged as a potential disease-modifying drug in type 1 diabetes (T1D). This meta-analysis sought to summarize the therapeutic effect of teplizumab in newly diagnosed patients with T1D.MethodsRandomized controlled trials involving patients with T1D receiving teplizumab in the intervention arm and placebo (or no active intervention) in the control arm were searched throughout the electronic databases. The primary outcome was the change in area under the curve of C-peptide levels from baseline.ResultsSeven reports from 6 studies involving 834 subjects met the inclusion criteria. Compared to teplizumab, greater reductions in area under the curve of C-peptide from the baseline values were observed in the control group after 6 months (mean difference [MD] 0.07 nmol/L [0.01, 0.13], P = .02), after 12 months (MD 0.07 nmol/L [0.04, 0.11], P = .0001), after 18 months (MD 0.10 nmol/L [0.06, 0.14], P < .00001), and after 24 months (MD 0.07 nmol/L [0.01, 0.14], P = .03) of interventions. Moreover, fewer patients treated with teplizumab had a decreased C-peptide response after 6 months (odds ratio [OR] 0.21), after 12 months (OR 0.17), after 18 months (OR 0.30), and after 24 months (OR 0.12) of treatment. The preservation of endogenous insulin production was supported by reduced use of exogenous insulin with maintenance of comparable glycemic control for up to 18 months post-treatment. Teplizumab imparted higher risks of grade 3 or higher adverse events, adverse events leading to study medication discontinuation, nausea, rash, and lymphopenia.ConclusionThe results of the meta-analysis support teplizumab as a promising disease-modifying therapy for newly diagnosed T1D.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被科研通管家采纳,获得10
刚刚
CipherSage的应助被科研通管家采纳,获得10
刚刚
orixero的应助被科研通管家采纳,获得10
刚刚
无花果的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
刚刚
zp的应助被科研通管家采纳,获得20
刚刚
FashionBoy的应助被科研通管家采纳,获得10
刚刚
1秒前
minting完成签到 ,获得积分10
1秒前
3秒前
3秒前
3秒前
3秒前
茉莉花发布了新的文献求助30
4秒前
carol7298发布了新的文献求助10
4秒前
fantasy的应助被小祝没吃饱采纳,获得10
6秒前
6秒前
Dyying发布了新的文献求助10
6秒前
经十路以东的应助被MMLi采纳,获得10
6秒前
7秒前
Chllerye发布了新的文献求助10
7秒前
7秒前
cdercder的应助被云隐采纳,获得10
8秒前
jxc完成签到,获得积分10
8秒前
gxy发布了新的文献求助10
8秒前
8秒前
旺仔发发发布了新的文献求助10
8秒前
nl完成签到 ,获得积分10
8秒前
超级灰狼完成签到 ,获得积分10
8秒前
8秒前
Orange的应助被风语村采纳,获得10
8秒前
9秒前
9秒前
9秒前
yyds的应助被阳光的灵竹采纳,获得10
9秒前
XX发布了新的文献求助10
11秒前
zzr完成签到 ,获得积分10
11秒前
小拉卡咪完成签到,获得积分20
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194041
求助须知:如何正确求助?哪些是违规求助? 9579979
关于积分的说明 21868799
捐赠科研通 7793641
什么是DOI,文献DOI怎么找? 3437477
关于科研通互助平台的介绍 2560942
邀请新用户注册赠送积分活动 2484251